Navigation Links
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Date:10/10/2008

WILMINGTON, Del., Oct. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR(R) (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex. SEROQUEL XR is the first medication approved by the FDA for the once-daily acute treatment of both depressive and manic episodes associated with bipolar disorder.(1)

"When people think about bipolar disorder it is important to remember how debilitating the depressive episodes of the disease can be. In fact, in the long term, patients with bipolar disorder experience depressive symptoms three times longer than manic symptoms," said Dr. Trisha Suppes, Professor of Psychiatry and Behavioral Sciences, Stanford University Medical Center and VA Palo Alto Health Care System. "With the approval of SEROQUEL XR for the treatment of bipolar depression and mania, we have a once-daily treatment that has been proven to help control the depressive and manic symptoms of bipolar disorder."

"These new indications for SEROQUEL XR mark an important milestone in the treatment of bipolar disorder," said Lisa Schoenberg, VP Specialty Care, AstraZeneca. "In addition to today's approval for the treatment of both the depressive and manic symptoms associated with this condition, SEROQUEL XR is now also approved as a long-term treatment option for bipolar I disorder."

About the SEROQUEL XR Bipolar Disorder Approval

Bipolar disorder, also known as manic depressive illness, is a serious psychiatric condition that consists of recurring episodes of depression and mania.(2) Approximately 8 million American adults may be affected by bipolar disorder.(3,4)

AstraZeneca submitted two separate
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...origami very high-tech origami. , Researchers at...ique for fabricating three-dimensional, single-cry...pling photolithography and a self-folding process ...ly a few microns thick, offer mechanical bendabili... same material. , "This is a completely different...
(Date:11/23/2009)...arbon layer in which the carbon atoms are arranged...arbon nanotubes are rolled-up sheets of graphene, ...Graphene boasts some very special characteristics ...mal conductor, and reconciles such conflicting qua...graphene is impermeable to gases, which makes it i...
(Date:11/23/2009)...irstCall/-YMBioSciencesInc.(NYSEAmex: YMI ;TSX:YM)...iesandadvancesadiverseportfolioofpromisingcancer-r...portedthatCytopia(ASX:CYT)hascommencedenrollmentof...inisteredJAK1/JAK2inhibitor.Thetrialisbeingconduct...geCytopiaintoYMhasbeenpreviouslyannouncedandispend...
(Date:11/23/2009)...poricidin disinfectant solution and wipes are reli...ainst H1N1 and Influenza A., , ... Contec Inc, the leading manufacturer of clean ro... disinfectants have been deemed by the EPA as eff...Pandemic 2009 H1N1 influenza A virus (the swine fl...
Breaking Biology Technology:Water droplets direct self-assembly process in thin-film materials 2Polymer with honeycomb structure 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 2
..., Mass., March 31 Tryton Medical, Inc., the,leadi... treatment of,bifurcation lesions announced today ... financing. Two new investors, PTV Sciences and Ri... Partners in the financing. Rick Anderson,from PTV...ted to the Tryton,Board of Directors., "Bifurcati...
...eneration Pyrosequencing(R) System; PyroMark(TM)Q2...or Low Throughput Epigenetic Studies, UPPSALA, Sw... Biotage AB today announced the launch of PyroMark...R) Systems. This new high-performance,platform inc... genetic and,epigenetic variation of genes, provid...
...Quarter 2008 Earnings Conference Call Thursday, Ma....S. EDT, FRAZER, Pa., March 31 Cephalon, Inc.,(...y earnings conference call,covering first quarter ...2008., May 1, 2008 Sched...tributed by PRNewswire 4:50 p.m. EDT To partic...
Other Biology Technology:Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3Biotage Launches New 24 Well Pyrosequencing(R) System 2
(Date:11/22/2009)...xposed prenatally to tobacco smoke and during chil...HD, according to research done at Cincinnati Child...ates that up to 35 percent of ADHD cases in childr...y eliminating both of these environmental exposure...n , "Tobacco and lead exposure each have their ...
(Date:11/22/2009)...r 23, 2009 Agios Pharmaceuticals today announced ...t time, that the mutated IDH1 gene has a novel enz..., or oncogene. This breakthrough discovery shows t..., 2-hydroxyglutarate (2HG), which may contribute t...as, the most common type of brain cancers. This di...
(Date:11/20/2009)... all read studies about the health benefits of hav...molecular level, where amino acids known as cystei... than when paired up with other cysteines. , Now... with colleagues in Belgium, have discovered a new.... The research appears in the Nov. 20 issue of the...
Breaking Biology News(10 mins):Exposure to lead, tobacco smoke raises risk of ADHD 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4Saving the single cysteine: New antioxidant system found 2Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 1Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 2Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 3The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 1The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 2The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 3The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 4The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 5Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 1Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 2Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 3
...tudy in 50 people in Japan suggests that eating tw...two months may confer some protection against a ra...d even stomach cancer. , Citing their new "demon...archer and an international team of scientists cau...id not cure infection by the bacterium Helicobact...
...ril 3 The General Services Administration (GSA) h...CH) as a provider of Personal Identity Verificatio...ation managed services, under Homeland Security Pr...fication, ABBTECH will offer services through thei...2 as an approved service provider. Services prov...
...chers from the Massachusetts General Hospital Cent... the first evidence of cell-to-cell communication ...ather than by known protein signaling agents such ... appear in an upcoming issue of the FASEB Journal... by complete surprise," says Rohit Jindal, PhD, a ...
Other Biology News:Gutsy germs succumb to baby broccoli 2Gutsy germs succumb to baby broccoli 3Gutsy germs succumb to baby broccoli 4ABBTECH Staffing Services Certified by GSA as an HSPD-12 Managed Service Provider 2Model tissue system reveals cellular communication via amino acids 2
Mouse Anti-GLP-1 Monoclonal Antibody, Unconjugated, Clone HYB 147-12 from Santa Cruz Biotechnology, Inc.
Baculovirus system service from Abgent
21-mer duplex design + syn.; 1 gene from B-Bridge International
EDTA, tetrasodium salt from GE Healthcare, formerly Amersham Biosciences
Biology Products: